The FDA approved the first-line maintenance therapy combining Jazz Pharmaceuticals' Zepzelca (lurbinectedin) with Roche's Tecentriq for extensive-stage small-cell lung cancer patients not progressing after first-line induction. Based on the positive Imforte Phase III data showing significant risk reductions in progression and death, this novel combination offers a new treatment pathway in a challenging oncologic indication.